Companies in #HER2-Positive Breast Cancer
Found 2 companies operating in this sector.
MacroGenics is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-based therapeutics for cancer. Its proprietary DART and TRIDENT bispecific platforms enable multi-specific targeting, and the company has one approved HER2-targeted breast cancer drug, Margenza (margetuximab-cmkb).
Radiopharm Theranostics is a clinical-stage radiopharmaceutical company developing paired diagnostic imaging and therapeutic candidates across several validated oncology targets, spanning peptides, small molecules and monoclonal antibodies radiolabelled with medical isotopes. Its pipeline pairs imaging agents such as 18F-RAD101 for recurrent brain metastases and Ga-68-RAD301 for pancreatic ductal adenocarcinoma with therapeutic assets including 177Lu-RAD202 in HER2-positive solid tumours and the B7-H3-targeted 177Lu-Betabart (RV-01) developed through a joint venture with MD Anderson Cancer Center. The company, which trades on both the ASX and Nasdaq, has a strategic agreement with Lantheus Holdings and isotope supply arrangements covering Lutetium-177 and Terbium-161.